288 related articles for article (PubMed ID: 25134801)
1. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors.
Sharma P; Arora S; Dhull VS; Naswa N; Kumar R; Ammini AC; Bal C
Abdom Imaging; 2015 Feb; 40(2):299-309. PubMed ID: 25134801
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified?
Sharma P; Arora S; Mukherjee A; Pal S; Sahni P; Garg P; Khadgawat R; Thulkar S; Bal C; Kumar R
Clin Nucl Med; 2014 Jan; 39(1):37-43. PubMed ID: 24152621
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma.
Sharma P; Thakar A; Suman K C S; Dhull VS; Singh H; Naswa N; Reddy RM; Karunanithi S; Kumar R; Kumar R; Malhotra A; Bal C
J Nucl Med; 2013 Jun; 54(6):841-7. PubMed ID: 23520216
[TBL] [Abstract][Full Text] [Related]
6. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen.
Mayerhoefer ME; Ba-Ssalamah A; Weber M; Mitterhauser M; Eidherr H; Wadsak W; Raderer M; Trattnig S; Herneth A; Karanikas G
Eur Radiol; 2013 Jul; 23(7):1978-85. PubMed ID: 23471430
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
Ambrosini V; Campana D; Bodei L; Nanni C; Castellucci P; Allegri V; Montini GC; Tomassetti P; Paganelli G; Fanti S
J Nucl Med; 2010 May; 51(5):669-73. PubMed ID: 20395323
[TBL] [Abstract][Full Text] [Related]
8. ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.
Naswa N; Sharma P; Kumar A; Soundararajan R; Kumar R; Malhotra A; Ammini AC; Bal C
Clin Nucl Med; 2012 Mar; 37(3):245-51. PubMed ID: 22310250
[TBL] [Abstract][Full Text] [Related]
9. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors.
Partelli S; Rinzivillo M; Maurizi A; Panzuto F; Salgarello M; Polenta V; Delle Fave G; Falconi M
Neuroendocrinology; 2014; 100(4):293-9. PubMed ID: 25301162
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes.
Sharma P; Mukherjee A; Karunanithi S; Naswa N; Kumar R; Ammini AC; Bal C
Clin Nucl Med; 2015 Jul; 40(7):e351-6. PubMed ID: 25783509
[TBL] [Abstract][Full Text] [Related]
11. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
13. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum.
Ilhan H; Fendler WP; Cyran CC; Spitzweg C; Auernhammer CJ; Gildehaus FJ; Bartenstein P; Angele MK; Haug AR
Ann Surg Oncol; 2015 Jan; 22(1):164-71. PubMed ID: 25190113
[TBL] [Abstract][Full Text] [Related]
14. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
15. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C
AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings.
Naswa N; Sharma P; Soundararajan R; Karunanithi S; Nazar AH; Kumar R; Malhotra A; Bal C
Abdom Imaging; 2013 Jun; 38(3):552-60. PubMed ID: 22743840
[TBL] [Abstract][Full Text] [Related]
17. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
[TBL] [Abstract][Full Text] [Related]
19. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
